Trial · NCT02106520
Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
NCT02106520, Phase 2, Phase 3, Terminated, Hospices Civils de Lyon
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT). Trials, record NCT02106520. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02106520
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
- NCT number
- NCT02106520
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 80 participants, actual
- Lead sponsor
- Hospices Civils de Lyon
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Epistaxis
- Interventions
- Bevacizumab, placebo
- First posted
- 2014-04-08
- Last updated
- 2015-11-20
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | mean duration of epistaxis | 3 months after treatment | To evaluate 3 months after the end of the treatment the efficacy on the duration of the nosebleeds with 3 different doses (25, 50 and 75 mg) of bevacizumab administered as a nasal spray in a repeated manner (3 administrations). |
| Secondary | adverse events | before and 6 months after treatment | Adverse events observed along a repeated administration of bevacizumab (nasal spray administration) : evaluation by epistaxis monitoring along the study and by a clinical exam before each treatment and 6 months after the end of the treatment. |
| Secondary | mean monthly epistaxis duration | 6 months after the end of the treatment | To evaluate the efficacy at 6 months after the end of the treatment on the duration of the nosebleeds for the dose retained versus placebo |
| Secondary | frequency and duration of epistaxis | 3 months and 6 months after the end of the treatment | Evolution of the frequency and the mean monthly duration of epistaxis at 3 and 6 months for the dose retained |
| Secondary | Quality of life | 3 months and 6 months aftert the end of the treatment | Evolution of the quality of life score (SF-36) between the inclusion, 3 months and 6 months after the end of the treatment |
| Secondary | Number of red blood cells transfusion | 3 months and 6 months after the end of the treatment | Evolution of the number of red blood cells transfusion between the inclusion and 3 and 6 months after the end of the treatment. |
| Secondary | Change in hemoglobinemia and serum ferritin | 1 month, 3 months and 6 months | Evolution of hemoglobinemia and serum ferritin at inclusion,3 and 6 months after the end of the treatment for the retained dose |
| Secondary | Kinetics of monthly epistaxis duration | 6 months | To describe the nosebleed kinetics for the dose retained and the placebo throughout the study |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27599328 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02106520
GET https://conductscience.org/api/trials/v1/NCT02106520/registered